Results 61 to 70 of about 46,312 (227)

Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses

BMC Cardiovascular Disorders, 2020
Background We evaluated adherence to dosing criteria for patients with atrial fibrillation (AF) taking dabigatran or rivaroxaban and the impact of off-label dosing on thromboembolic and bleeding risk.
Alexandros Briasoulis, Yubo Gao, Chakradhari Inampudi, Paulino Alvarez, Rabea Asleh, Elizabeth Chrischilles, Enrique C. Leira, Mary Vaughan-Sarrazin   +7 more
doaj   +1 more source

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2016
Background The introduction of non–vitamin K antagonist oral anticoagulants has been a major advance for stroke prevention in atrial fibrillation; however, outcomes achieved in clinical trials may not translate to routine practice.
Xiaoxi Yao, N. Abraham, L. Sangaralingham, M. Bellolio, R. McBane, Nilay D. Shah, P. Noseworthy   +6 more
semanticscholar   +1 more source

Idarucizumab more effectively reverses the anticoagulant effects of dabigatran acylglucuronide than dabigatran

Scientific Reports
Dabigatran acylglucuronide, an active metabolite of dabigatran, exhibits higher plasma concentrations and distinct anticoagulant effects compared to dabigatran, suggesting that it may play a more significant role in overall anticoagulant activity than ...
Jong-Min Kim, Young Yoon Bang, Kyoung-Ah Kim, Jin-Woo Park, Ji-Young Park   +4 more
doaj   +1 more source

The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillation

BMC Cardiovascular Disorders, 2022
Background This study aimed to analyze associations between genetic variants and plasma concentrations along with clinical outcomes in dabigatran in patients with non-valvular atrial fibrillation (NVAF).
Zhu Zhu, Chenyue Qian, Cunjing Su, Hong Tao, Jiaojiao Mao, Zhening Guo, Xinyi Zhu, Jie Pan   +7 more
doaj   +1 more source

Update on Extended Treatment for Venous Thromboembolism [PDF]

, 2018
The importance of assessing the probability of venous thromboembolism recurrence, a condition that includes deep vein thrombosis and pulmonary embolism, lies in the fact that it is the most important factor in deciding the duration of anticoagulant ...
Del Toro-Cervera, Jorge, Demelo-Rodríguez, Pablo, Llamazares-Mendo, Cristina, Marra, Alberto M, Peñaloza-Martínez, Eduardo, Proietti, Marco, Soria Fernández-Llamazares, Guillermo, Álvarez-Sala Walther, Luis   +7 more
core   +2 more sources

Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children.

Blood, 2019
This open-label, single-arm, prospective cohort trial is the first phase 3 safety study to describe outcomes in children treated with dabigatran etexilate for secondary venous thromboembolism (VTE) prevention. Eligible children aged 12 to
L. Brandão, M. Albisetti, J. Halton, L. Bomgaars, E. Chalmers, L. Mitchell, I. Nurmeev, P. Svirin, T. Kuhn, O. Zapletal, I. Tartakovsky, Monika Simetzberger, F. Huang, Zhichao Sun, J. Kreuzer, S. Gropper, M. Brueckmann, M. Luciani   +17 more
semanticscholar   +1 more source

The Protective Effect of Dabigatran and Rivaroxaban on DNA Oxidative Changes in a Model of Vascular Endothelial Damage with Oxidized Cholesterol

International Journal of Molecular Sciences, 2020
Background: Atherosclerotic plaques are unstable, and their release may result in thrombosis; therefore, currently, antiplatelet therapy with anticoagulants is recommended for the treatment of acute coronary syndrome.
E. Woźniak, M. Broncel, B. Bukowska, P. Gorzelak-Pabiś   +3 more
semanticscholar   +1 more source

New oral anticoagulants and their reversal agents [PDF]

, 2018
Atrial fibrillation is a commonly encountered pathology in medical practice, and its prevalence has shown a continuous rise over the past years. Atrial fibrillation has a significant impact on patients\u27 quality of life, not only due to the standard ...
Bodean, Oana, Diaconu, Camelia C, Laslo, Crista L, Marcu, Dragos, Neagu, Tiberiu P, Paduraru, Dan N, Pantea Stoian, Anca, Socea, Bogdan, Socea, Laura I, Stanescu, Ana Maria Alexandra   +9 more
core   +1 more source

Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [PDF]

, 2014
Background: Dabigatran is a novel oral anticoagulant approved for thromboprophylaxis in atrial fibrillation. Adoption patterns of this new agent in community practice are unknown.
Ansell, Jack, Chang, Paul, Ezekowitz, Michael D., Fonarow, Gregg C., Gersh, Bernard, Holmes, DaJuanicia N., Hylek, Elaine M., Kowey, Peter R., Mahaffey, Kenneth W., Peterson, Eric D., Piccini, Jonathan P., Singer, Daniel E., Steinberg, Benjamin A., Thomas, Laine   +13 more
core   +1 more source

Long-Term Dabigatran Treatment Delays Alzheimer's Disease Pathogenesis in the TgCRND8 Mouse Model.

Journal of the American College of Cardiology, 2019
BACKGROUND Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder with important vascular and hemostatic alterations that should be taken into account during diagnosis and treatment.
M. Cortes-Canteli, A. Kruyer, Irene Fernandez‐Nueda, Ana Marcos-Díaz, C. Céron, Allison T. Richards, Odella Jno-Charles, I. Rodríguez, S. Callejas, E. Norris, J. Sánchez-González, J. Ruíz-Cabello, B. Ibáñez, S. Strickland, V. Fuster   +14 more
semanticscholar   +1 more source